Adapting the Shed-MEDS Deprescribing Intervention to Dementia Care in Assisted Living
Status
Conditions
Treatments
Details and patient eligibility
About
This single-arm pilot study will evaluate the effects of an intervention to reduce exposure to unnecessary or potentially harmful medications among residents with dementia living in an assisted living facility. The goal of the intervention is to safely deprescribe medications (defined by dose reductions and stopped medications), based on a combination of clinical criteria and resident/surrogate preferences. The investigators will evaluate the effects of the intervention on the total number of medications deprescribed from enrollment at 30, 60, and 90 days along with resident/surrogate reports of quality of life at enrollment and 90 days.
Full description
This single-arm pilot trial will evaluate an evidence-based, patient-centered deprescribing intervention with assisted living facility (ALF) residents age 65+ who have a diagnosis of dementia. This deprescribing intervention was demonstrated to be safe and effective in reducing medication burden during the Shed-MEDS randomized clinical trial that enrolled hospitalized older adults discharging to post-acute care facilities. The intervention includes a comprehensive review of a participant's medications by the study's clinician and deprescribing recommendations using evidence-based guidelines. Deprescribing recommendations will be shared with residents/surrogate decision makers (i.e., respective family member/s) to determine their willingness to stop or reduce the dose of the targeted medications. If the resident/surrogate-decision maker agrees, deprescribing recommendations will then be communicated with the routine ALF medical providers for consideration and final deprescribing decisions.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Resident of assisted living facility
- Speaks English (due to interview-based assessments)
- Diagnosis of dementia
- Taking a total of 5 medications or at least one potentially inappropriate medication (defined by the Beers criteria, STOPP criteria, and the Rationalization of home medication by an Adjusted STOPP in older Patients [RASP])
- Able self-consent or has a proxy (surrogate)
Exclusion criteria
- None
Trial design
Primary purpose
Allocation
Interventional model
Masking
Trial contacts and locations
Loading...
Central trial contact
Sandra Simmons, PhD; Jennifer Kim, DNP
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal